Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 12/20 | 0.41 |
| ▸ | ROS1 | P08922 | 12/20 | 0.41 |
| ▸ | FLT3 | P36888 | 12/20 | 0.41 |
| ▸ | EML4 | Q9HC35 | 8/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 8/20 | 0.41 |
| ▸ | SYK | P43405 | 4/20 | 0.38 |
| ▸ | BTK | Q06187 | 2/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30205554 | 1.00 | RET (0.41) | RETROS1FLT3EML4ALK | |
| SCHEMBL30206131 | 0.92 | EGFR (0.34) | RETROS1FLT3EML4ALK | |
| SCHEMBL30206167 | 0.90 | EML4 (0.41) | RETROS1FLT3EML4ALK | |
| SCHEMBL30205565 | 0.89 | EML4 (0.40) | RETROS1FLT3EML4ALK | |
| SCHEMBL29173301 | 0.89 | BTK (0.39) | RETROS1FLT3EML4ALK | |
| SCHEMBL24944410 | 0.89 | RET (0.38) | RETROS1FLT3EML4ALK | |
| Formic Acid SCHEMBL30205747 | 0.88 | BTK (0.37) | RETROS1FLT3EML4ALK | |
| Formic Acid SCHEMBL30205528 | 0.88 | RET (0.36) | RETROS1FLT3EML4ALK | |
| SCHEMBL24944782 | 0.87 | RET (0.49) | RETROS1FLT3EML4ALK | |
| SCHEMBL24943791 | 0.87 | EML4 (0.48) | RETROS1FLT3EML4ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023001794-A1 | SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2023-01-26 | — | — | WO | disclosed |